Industry Symposium 10

18:45-19:45   Hall K

Treating secondary hyperparathyroidism with calcimimetics; new insights

Chair: David Wheeler, London, United Kingdom

Lessons learnt from the EVOLVE study
Jürgen Floege, Aachen, Germany
Etelcalcetide - a new injectable calcimimetic for the treatment of secondary hyperparathyroidism
Markus Ketteler, Coburg, Germany

Organised by AMGEN

back to timetable

back to timetable

final programme "day by day" - may 21 - 24, 2016